5th UK Diagnostics Forum

26–27 May 2016
Lady Margaret Hall, Oxford
UK Diagnostics Forum 2016
Organised by the NIHR Diagnostic Evidence Co-operative Oxford, in collaboration with NICE, Innovate UK and the British In Vitro Diagnostics Association (BIVDA), this is a meeting of industry, academia and healthcare, developing ways to facilitate the utilisation and adoption of innovative tests through good quality evidence.
www.oxford.dec.nihr.ac.uk

Notice of photography and filming
The UK Diagnostics Forum is being visually documented. By attending, you acknowledge that you have been informed that you may appear in photographs or videos taken during this event. Images taken will be treated as the property of NIHR Diagnostic Co-operative Oxford and may be used in the future for promotional purposes. These images may be used without limitation by any organisation approved by NIHR DEC Oxford and edited prior to publication. Images will be available on the internet accessible to internet users throughout the world including countries that may have less extensive data protection laws than partnering countries. All films will be securely stored on University of Oxford servers. Please make yourself known at the registration desk if you wish to remain off camera.
Welcome to the 5th UK Diagnostics Forum

It is with great pleasure that I welcome you to the 5th UK Diagnostics Forum. This year’s theme is about how diagnostics can change more than delivering diagnostic information alone. They could have an impact on where in the healthcare system patients are diagnosed and treated, and by whom. Moreover, easy-to-use tests can allow patients to manage their own health. New diagnostic technology could make things easier, but could also require a redesign of how we do things. We believe it’s worth thinking about these changes, and a better understanding of them will facilitate successful uptake of diagnostic innovations.

We are happy to present a very interesting programme around this theme of disruptive diagnostics, with speakers from industry, the NHS and academia. Our first keynote speaker is followed by a panel discussion on the changes new tests might induce: your views, thoughts or comments are more than welcome! We continue tomorrow with more talks on new service models, patient involvement, and diagnostic innovations for specific settings. We will also present and discuss some examples of industry-academia-healthcare collaborations. In between, there is ample opportunity for networking and informal discussion over lunch, coffee breaks and dinner.

As in previous years, this year’s Forum has been organised in partnership with Innovate UK, BIVDA and NICE. I’d like to take this opportunity to thank my fellow organisers for their input.

Let’s start the Forum!
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-16.15</td>
<td>Registration and tea/coffee</td>
<td></td>
<td>Simpkins-Lee Foyer</td>
</tr>
<tr>
<td>16.15-16.30</td>
<td>Ann Van den Bruel, Director, NIHR DEC Oxford</td>
<td>Welcome</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td>16.30-17.30</td>
<td>Ken Paterson, NHS Scotland</td>
<td>Disruptive innovation in healthcare</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td>17.30-18.30</td>
<td>Panel discussion chaired by Ann Van den Bruel</td>
<td>Disruptive diagnostics</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td></td>
<td>Panel members:</td>
<td><em>There will be an opportunity to ask questions</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chris Butler, Academic GP, University of Oxford</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Brian Shine, Pathologist, Oxford University Hospitals Foundation Trust</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Eve Knight, Anti-Coagulation Europe</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Chris Hudson, Roche</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ken Paterson, NHS Scotland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30-20.30</td>
<td>Drinks reception</td>
<td>Networking</td>
<td>Talbot Hall</td>
</tr>
<tr>
<td>20.30</td>
<td>Dinner</td>
<td></td>
<td>Deneke Hall</td>
</tr>
<tr>
<td>Time</td>
<td>Speaker</td>
<td>Topic</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>9.00-9.30</td>
<td>Dan Lasserson, Oxford University Hospitals Foundation Trust</td>
<td>New models of care supported by diagnostic technology</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td>9.30-10.00</td>
<td>Kate Silvester, Healthcare Systems Engineer</td>
<td>Lean thinking in healthcare</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Eve Knight, Anti-Coagulation Europe</td>
<td>INR monitoring for anticoagulation treatment</td>
<td>Simpkins-Lee lecture theatre</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td></td>
<td></td>
<td>Monson room</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Sally Chisholm, Programme Director for Adoption and Impact, NICE</td>
<td>Barriers and solutions to the adoption of diagnostic technologies</td>
<td>Simpkins Lee Lecture Theatre</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Tracey Marriott, Oxford AHSN</td>
<td>Accelerating Innovation Adoption in the NHS</td>
<td>Simpkins Lee Lecture Theatre</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Chris Hudson, Roche Diagnostics</td>
<td>Tests as part of a wider system</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td></td>
<td></td>
<td>Monson room</td>
</tr>
<tr>
<td></td>
<td>Lucy Abel, University of Oxford</td>
<td>There will be an opportunity to ask questions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sara Graziadio, NIHR DEC Newcastle</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Melody Ni, NIHR DEC London</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parallel sessions</td>
<td>Networking, posters, exhibitions</td>
<td>Monson Room</td>
</tr>
<tr>
<td>14.30-15.15</td>
<td>Rosanna Peeling, Director, International Diagnostics Centre, LSHTM</td>
<td>Diagnostics in a Digital Age: Promises and Challenges</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
<tr>
<td>15.15-15.30</td>
<td>Ann Van den Bruel, Director NIHR DEC Oxford</td>
<td>Summary and close</td>
<td>Simpkins-Lee Lecture Theatre</td>
</tr>
</tbody>
</table>
Chris Butler, Professor of Primary Care, University of Oxford

Chris is Professor of Primary Care in the Nuffield Department of Primary Care Health Sciences, Professorial Fellow at Trinity College, and is the Clinical Director of the University of Oxford Primary Care Clinical Trials Unit. He is a National Institute for Health Research (NIHR) Senior Investigator, and practices as a salaried GP in Mountain Ash in South Wales for the Cwm Taf University Health Board. His main research interests are in common infections (especially the appropriate use of antibiotics and antibiotic resistance), and health behaviour change (especially adaptations of motivational interviewing in health care).

Sally Chisholm, NICE Programme Director: Health Technologies Adoption Programme

Sally has responsibility for supporting the implementation of all forms of NICE guidance and quality standards. As well as providing data to support guidance development Sally’s role includes producing support products to measure the resource impact of guidance and monitoring of its uptake and impact. In 2010 Sally was awarded an MBA (Open) and took up her post as the Chief Executive of the NHS Technology Adoption Centre. She joined NICE in 2013.

Chris Hudson, Director, Healthcare Development and Strategic Services, Roche

Chris joined Roche in Oct 1998 as Marketing Manager UK and Ireland for Patient Monitoring. He was promoted to Director in 2001 and subsequently became Director of Diabetes Care UK in 2005. In 2007 Chris moved to Global DC as Head of Commercial Marketing and became Head of BGM Marketing RDC global in 2009. Moving back to the UK as Director of RTD in 2010, he became Director of Healthcare Development and Strategic Services in 2015. Prior to Roche Chris worked in marketing and sales for several international healthcare companies in the UK and USA.

Eve Knight Co-founder and CEO AntiCoagulation Europe

Eve has co-authored many articles for health publications. She has been a member of boards including the Government Modernisation Board for the NHS, external advisory group for the National Service Framework for Coronary Heart Disease and the National CHD Task Force. She is section editor for the British Journal of Cardiology and the British Journal of Primary Care Nursing.

Dan Lasserson, Associate Professor, University of Oxford

Dan is the Clinical Lead for Diagnostics and Pathways in the Oxford Academic Health Science Network. He is a senior interface physician in acute and complex medicine in the Department of Geratology, Oxford University Hospitals NHS Foundation Trust. This continues his earlier collaborative work across the acute trust, community trust and University in Oxford that set up the Emergency Multidisciplinary Unit which won the 2013 Guardian Healthcare Innovation Award for Service Delivery. He is a member of the NICE Acute Medical Emergencies guideline development group and is the co-chair of the Measurement Workstream of NHS England’s Acute Kidney Injury Programme ‘Think Kidneys’.
Tracey Marriott, Oxford AHSN

Tracey is an MBA qualified transformational change professional with extensive experience of delivering complex programmes both nationally and within the Oxford AHSN region. She works closely with the Oxford AHSN Best Care Clinical Networks, service providers, NHS commissioners and suppliers for innovation implementation.

Kenneth R Paterson, NHS Scotland

Ken was appointed Consultant Physician with interest in diabetes mellitus at Glasgow Royal Infirmary in 1986. He was actively involved in the wider world of diabetes, forming the Glasgow Local Diabetes Services Advisory Group and hairing a SIGN guideline development group looking at diabetic renal disease. Ken’s other interests include clinical pharmacology and therapeutics and, after many years as Vice-Chair of his local Area Drug and Therapeutics Committee, became Chair of the New Drugs Committee of the Scottish Medicines Consortium (SMC) in 2004 and held the Chair of SMC from 2008 to 2011. He is currently a Member of the Board of the Faculty of Pharmaceutical Medicine.

Rosanna Peeling, Professor and Chair of Diagnostics Research, Director of International Diagnostics Centre, LSHTM

Rosanna is currently Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine and Director of the International Diagnostic Centre (IDC). Trained as a medical microbiologist, she was Research Coordinator and Head of Diagnostics Research at the World Health Organization in Geneva and the co-Director of the Canadian National Laboratory for Sexually Transmitted Diseases before assuming her current position. Her work spans from facilitating test development and evaluation to the translation of evidence to inform policy, and strategic placement of new diagnostic technologies to ensure maximum impact. She established the IDC to advocate the value of diagnostics, foster innovation, and accelerate access to quality-assured diagnostics to improve global health.

Brian Shine, Pathologist, Oxford University Hospitals Foundation Trust

Brian qualified in Medicine from the University of Zimbabwe in 1974. He trained in Chemical Pathology at St. Bartholomew's Hospital, London, where he did an MD on C-reactive protein. He holds an MSc in Applied Statistics and Operations Research from the University of London. He was a Senior Lecturer at the Institute of Ophthalmology and Moorfields Eye Hospital, and consultant at Stoke Mandeville Hospital. Current appointments include Consultant Chemical Pathologist in the Department of Clinical Biochemistry, Oxford Radcliffe Hospitals, Honorary Senior Clinical Lecturer in the Nuffield Department of Clinical Laboratory Sciences, Research Associate in the Diabetes Trials Unit, Consultant to Diabetes Trials Unit laboratory, and Chair of Oxford Research Ethics Committee A. His clinical interests are in Endocrinology and Diabetes, particularly lipids, thyroid disease, polycystic ovaries disease, and neuroendocrine tumours. Research interests include modelling reference intervals and quality assurance.

Kate Silvester, Healthcare Systems Engineer

Kate originally trained as an ophthalmologist and retrained as a manufacturing engineer. She has 20 years’ experience transferring manufacturing principles to healthcare. She works internationally with healthcare organisations to improve patient safety by improving emergency and elective patient flow. In her last programme for The Health Foundation she coached 2 NHS Trusts and demonstrated the impact of poor patient flow on death rates and cost and how to improve them. Kate was appointed to the Faculty of the Institute of Healthcare Improvement in 2001 and an honorary associate professor at the University of Warwick in 2006. She now works independently and with an international network of healthcare design and improvement practitioners.
Lucy Abel, Health Economist, University of Oxford

Lucy joined the Nuffield Department of Primary Care Health Sciences in July 2015 as a health economist working within the field of primary care. The core of her role is in collaborating with other research groups to bring the tools of economic evaluation to primary care health science research. Lucy’s current research uses decision analytical modelling to assess the cost-effectiveness of different strategies for diagnosing multiple myeloma in primary care. This also formed the basis of the dissertation for her MSc in Health Economics from the University of York.

Sara Graziadio, IVD Evaluation Methodologist, NIHR DEC Newcastle

Sara joined the NIHR Newcastle DEC in August 2015 after being a Research Associate at Institute of Neuroscience, Newcastle University since 2009. She is a scientist with ten years’ training in statistics and has a strong academic background in the analysis and interpretation of large and complex datasets. Sara has significant knowledge of study design, and extensive experience of project coordination - facilitating national and international collaborations.

Melody Ni, Imperial DEC, London

Melody is a senior methodologist within DEC London. She studied Decision Sciences at the London School of Economics and has been applying decision analysis methodologies to medicine since 2007. Her research focuses on improving decision making where uncertainties abound, generating evidence where it is scarce, and handling data that are heterogeneous. She and her colleagues at DEC London are developing methods for efficient evidence generation which would take into account perspectives from multiple stakeholders and for technologies at various stages of development.

Philip Turner, Researcher and Industry Liaison Lead, NIHR DEC Oxford

Phil is the researcher within the Oxford DEC who is responsible for liaising with members of the in vitro diagnostics industry and for facilitating interactions with the DEC advisory panel. He has a specific interest in IVDs which could be deployed in resource-limited settings. Phil’s background is in cell physiology, membrane transport processes and signaling. He has a particular interest in the control of ventilation and specifically how humans respond to changes in the partial pressure of inspired oxygen. Phil also has an associated interest in the physiology and medicine of life in remote regions and at high altitude.
Organising committee

Carla Deakin, Associate Director Diagnostics Assessment Programme, NICE
Having started her career as a biomedical scientist, Carla moved into the UK in vitro diagnostics industry where she spent the following 25 years gaining both commercial and healthcare system experience in a variety of roles. Carla moved to NICE in February 2014 as Associate Director for the Diagnostics Assessment Programme and holds a PGDip in Health Economics and Health Policy.

Chris Price Visiting Professor in Clinical Biochemistry, University of Oxford
Chris trained as a clinical biochemist and his early career was spent in the National Health Service. He was Professor of Clinical Biochemistry at the St Bartholomew’s and Royal London School of Medicine and Dentistry from 1988 to 2001, and Director of Laboratory Medicine at the Barts and London NHS Trust from 1993 to 2001. From 2002 and 2005 he was Vice President of Outcomes Research in the Diagnostics Division of Bayer Health Care. He was Clinical Director of the Cumbria and Lancashire Pathology Commissioning Network between 2009 and 2011.

Carla Deakin, Associate Director Diagnostics Assessment Programme, NICE

Ann Van den Bruel, Associate Professor, Director, NIHR DEC Oxford
Ann is the Director of the NIHR Diagnostic Evidence Co-operative Oxford which aims to facilitate diagnostic innovations in the NHS. They offer training and advice for anyone who is developing a new diagnostic test for primary care. In addition to research, Ann is also involved in teaching for the Centre for Evidence Based Medicine and other institutions across Europe.

Doris-Ann Williams MBE, Chief Executive, BIVDA
Doris-Ann has been Chief Executive of BIVDA since October 2001. She has more than 30 years’ experience working in the IVD sector; initially in R&D and subsequently in commercial roles including international responsibilities. She is on the Editorial board of IVD Technology and on steering groups for the Technology Strategy Board and NHS Implementation Board for Innovation, Health and Wealth, and works closely with EDMA and other global IVD industry associations. She was awarded an MBE in January 2011 and Friend of the Royal College of Pathologists in November 2012.

Penny Wilson, Innovation Platform Leader, Innovate UK
Penny has spent over 20 years in the diagnostics industry in a variety of senior technical and strategic roles. In recent years she has focused on point-of-care diagnostic systems from both a technical and societal perspective and on the challenges of technology integration and adoption. Her expertise spans human, animal and plant diagnostics and she has considerable expertise in assessing the diagnostic and healthcare needs in both the developed and developing world.
The exhibition will be open throughout the Forum in the Monson Room

Exhibitors:

Aquarius
Biotoolomics
Capillary Film Technology
Cepheid
CliniTech
Device Access
NALIA Systems
Perspectum Diagnostics
Proxsis
RB

There will also be a chance to play ‘DECisons’ the diagnostic board game, designed to help illustrate the evidence gathering and regulatory pathway that a new diagnostic test would have to follow in order for the device to be implemented in clinical practice.
Partners

Innovate UK is the UK's innovation agency. We work with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.

The British In Vitro Diagnostics Association is the national industry association for companies with major involvement and interest in the in vitro diagnostics (IVD) industry. BIVDA represents both manufacturers and distributors who are active in the UK.

The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care.
Diagnostic Evidence Workshop 2016

27-28 September 2016
Worcester College, Oxford
The NIHR Diagnostic Evidence Co-operative (DEC) Oxford two day course on diagnostic test development, evaluation and regulation.

Day 1
• Tests as part of a clinical pathway
• Aligning research and development with clinical needs
• Different forms of evidence for different types of questions
• How to avoid low-quality studies workshop
• Searching to support regulatory approval and other purposes

Day 2
• Evidence for regulatory purposes
• Evidence for implementation in routine clinical practice - NICE evaluations
• Basic stats in diagnostic studies
• Funding for diagnostic test development/opportunities for collaboration with academia

Registration details: www.oxford.dec.nihr.ac.uk/courses-and-events

This course is aimed at all professionals working on diagnostic tests including people working in industry, academia, funding and regulation. During the two day course we will provide you with the latest information on what evidence is needed to obtain regulatory approval, how NICE evaluates new diagnostic technology and how to collect evidence to support adoption in routine clinical practice. In addition, we will teach you about different study designs including quality assessment, and where to look for funding opportunities. The course combines talks with hands-on activities. To stimulate interactive discussions and maximise the learning experience, the number of places for this course are limited to 25 spaces.

#DECOx16